Vinpocetine attenuates MPTP-induced motor deficit and biochemical abnormalities in Wistar rats

Neuroscience

Volumn 286, Issue , 2015, Pages 393-403

  Sharma, S ^a   Deshmukh, R ^a  

^a ISF COLLEGE OF PHARMACY   (India)

Author keywords

Cyclic nucleotides; MPTP; Parkinson's disease; PDE1; Phosphodiesterases; Vinpocetine

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CYCLIC AMP; CYCLIC GMP; DOPAMINE; GLUTATHIONE; INTERLEUKIN 1BETA; MALONALDEHYDE; NITRITE; PHOSPHODIESTERASE I; TUMOR NECROSIS FACTOR ALPHA; VINPOCETINE; PHOSPHODIESTERASE INHIBITOR; VINCA ALKALOID;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN LEVEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MECHANISM; EXPERIMENTAL BEHAVIORAL TEST; EXPERIMENTAL LOCOMOTOR ACTIVITY TEST; FALLING; GRIP STRENGTH; LATENT PERIOD; MALE; MOTOR DYSFUNCTION; MPTP-INDUCED PARKINSONISM; NARROW BEAM WALK TEST; NEUROPROTECTION; NITROSATIVE STRESS; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; RAT; ANIMAL; CHEMISTRY; CORPUS STRIATUM; DRUG EFFECTS; ENCEPHALITIS; METABOLISM; MOTOR ACTIVITY; PARKINSONIAN DISORDERS; SUBSTANTIA NIGRA PARS COMPACTA; WISTAR RAT;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; CORPUS STRIATUM; CYCLIC AMP; CYCLIC GMP; ENCEPHALITIS; MALE; MOTOR ACTIVITY; OXIDATIVE STRESS; PARKINSONIAN DISORDERS; PARS COMPACTA; PHOSPHODIESTERASE INHIBITORS; RATS; RATS, WISTAR; VINCA ALKALOIDS;

EID: 84920175879     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2014.12.008     Document Type: Article

References (61)

1. Abdel S.O.M., Khadrawy Y.A., Salem N.A., Sleem A.A. Oxidative stress in a model of toxic demyelination in rat brain: the effect of piracetam and vinpocetine. Neurochem Res 2011, 36:1062-1072.
2. Carter R.J. Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J Neurosci 1999, 19:3248-3257.
3. Chalimoniuk M., Lukacova N., Marsala J., Langfort J. Alterations of the expression and activity of midbrain nitric oxide synthase and soluble guanylyl cyclase in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in mice. Neuroscience 2006, 141:1033-1046.
4. Chen X., Xu L., Radcliffe P., Sun B., Tank A.W. Activation of tyrosine hydroxylase mRNA translation by cAMP in midbrain dopaminergic neurons. Mol Pharmacol 2008, 73:1816-1828.
5. Dastidar S.G., Rajagopal D., Ray A. Therapeutic benefit of PDE4 inhibitors in inflammatory diseases. Curr Opin Investig Drugs 2007, 8:364-372.
6. Deshmukh R., Sharma V., Mehan S., Sharma N., Bedi K.L. Amelioration of intracerebroventricular streptozotocin induced cognitive dysfunction and oxidative stress by vinpocetine - a PDE1 inhibitor. Eur J Pharmacol 2009, 620:49-56.
7. Drechsel D.A., Liang L.P., Patel M. 1-Methyl-4-phenylpyridinium-induced alterations of glutathione status in immortalized rat dopaminergic neurons. Toxicol Appl Pharmacol 2007, 220:341-348.
8. Ellman G.L. Tissue sulfhydryl groups. Arch Biochem Biophys 1959, 82:70-77.
9. Feng L., Wang C.Y., Jiang H., Oho C., Mizuno K., Dugich-Djordjevic M., Lu B. Differential effects of GDNF and BDNF on cultured ventral mesencephalic neurons. Brain Res Mol Brain Res 1999, 66:62-70.
10. Garcia M.J.A., Miriam R., Sandra A.G., Carmen G., Concepcion P., Ana M., Santos A., Perez-Castillo A. Phosphodiesterase 7 inhibition preserves dopaminergic neurons in cellular and rodent models of Parkinson disease. PLoS One 2011, 6:e17240.
11. Green L.C., Wagner D.A., Glgowski J., Skipper P.L., Wishnok J.S., Tannebaum S.R. Analysis of nitrate, nitrite and [15N] nitrate in biological fluids. Ann Biochem Exp Med 1982, 126:131-135.
12. Greengard P. The neurobiology of slow synaptic transmission. Science 2001, 294:1024-1030.
13. Hakansson K., Lindskog M., Pozzi L., Usiello A., Fisone G. DARPP-32 and modulation of cAMP signaling: involvement in motor control and levodopa-induced dyskinesia. Parkinsonism Relat Disord 2004, 10:281-286.
14. Halliwell B. Reactive oxygen species and the central nervous system. J Neurochem 1992, 59:1609-1623.
15. Hastings T.G. Enzymatic oxidation of dopamine: the role of prostaglandin H synthase. J Neurochem 1995, 64:919-924.
16. Hirsch E.C., Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection?. Lancet Neurol 2009, 8:382-397.
17. Horvath B., Marton Z., Halmosi R., Alexy T., Szapary L., Vekasi J., Biro Z., Habon T., Kesmarky G., Toth K. In vitro antioxidant properties of pentoxifylline, piracetam, and vinpocetine. Clin Neuropharmacol 2002, 25:37-42.
18. Hung H.C., Lee E.H. The mesolimbic dopaminergic pathway is more resistant than the nigrostriatal dopaminergic pathway to MPTP and MPP+ toxicity: role of BDNF gene expression. Brain Res Mol Brain Res 1996, 41:14-26.
19. Hyman C., Hofer M., Barde Y.A., Juhasz M., Yancopoulos G.D., Squinto S.P., Lindsay R.M. BDNF is a neurotrophic factor for dopaminergic neurons of the substantia nigra. Nature 1991, 350:230-232.
20. Jenner P. Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci 2008, 9:665-677.
21. Kakkar R., Raju R.V.S., Rajput A., Sharma R.K. Amantadine: an anti Parkinsonian agent inhibits bovine 60kDa calmodulin-dependent cyclic nucleotide phosphodiesterase isozyme. Brain Res 1997, 749:290-294.
22. Kreutzberg G.W. Microglia: a sensor for pathological events in the CNS. Trends Neurosci 1996, 19:312-318.
23. Kumer S.C., Vrana K.E. Intricate regulation of tyrosine hydroxylase activity and gene expression. J Neurochem 1996, 67:443-462.
24. Laddha S.S., Bhatnagar S.P. A new therapeutic approach in Parkinson's disease: some novel quinazoline derivatives as dual selective phosphodiesterase 1 inhibitors and anti-inflammatory agents. Bioorg Med Chem 2009, 17:6796-6802.
25. Lesch K.P., Lerer B. The 5-HT receptor-G-protein-effector system complex in depression. I. Effect of glucocorticoids. J Neural Transm Gen Sect 1991, 84:3-18.
26. Levivier M., Przedborski S., Bencsics C., Kang U.J. Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson's disease. J Neurosci 1995, 15:7810-7820.
27. Lima M.M.S., Reksidler A.B., Zanata S.M., Machado H.B., Tufik S., Vital M.A. Different Parkinsonism models produce a time-dependent induction of COX-2 in the substantia nigra of rats. Brain Res 2006, 1101:117-125.
28. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem 1951, 193:265-275.
29. Medina A.E. Vinpocetine as a potent anti inflammatory agent. PNAS 2010, 107:9921-9922.
30. Menalled L.B., Patry M., Ragland N., Lowden P.A.S., Goodman J., Minnich J., Zahasky B., Park L., Leeds J. Comprehensive behavioral testing in the R6/2 mouse model of Huntington's disease shows no benefit from CoQ10 or minocycline. PLoS One 2010, 5:1-12.
31. Mohapel P., Frielingsdorf H., Haggblad J., Zachrisson O., Brundin P. Platelet-derived growth factor (PDGF-BB) and brain-derived neurotrophic factor (BDNF) induce striatal neurogenesis in adult rats with 6-hydroxy dopamine lesions. Neuroscience 2005, 132:767-776.
32. Neve K.A., Seamans J.K., Trantham-Davidson H. Dopamine receptor signaling. J Recept Signal Transduct Res 2004, 24:165-205.
33. Nishi A., Kuroiwa M., Miller B.D. Distinct roles of PDE4 and PDE10A in the regulation of cAMP/PKA signaling in the striatum. J Neurosci 2008, 28:10460-10471.
34. Nishino N., Kitamura N., Hashimoto T., Tanaka C. Transmembrane signalling systems in the brain of patients with Parkinson's disease. Rev Neurosci 1993, 4:213-222.
35. Patel B.A., Arundell M., Parker K.H., Yeoman M.S., O'Hare D. Simple and rapid determination of serotonin and catecholamines in biological tissue using high-performance liquid chromatography with electrochemical detection. J Chromatogr B Analyt Technol Biomed Life Sci 2005, 818:269-276.
36. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 2005, Academic Press, London. 5th ed.
37. Porritt M.J., Batchelor P.E., Howells D.W. Inhibiting BDNF expression by antisense oligonucleotide infusion causes loss of nigral dopaminergic neurons. Exp Neurol 2005, 192:226-234.
38. Ratra M., Sharma P.L., Gupta R. Evaluation of vinpocetine on locomotor activity in 3-NP induced rats. Inventi Rapid Mol Pharmacol 2011, 2011:2. Article ID-Inventi:pmp/119/11.
39. Reksidler A.B., Lima M.M., Dombrowski P., Andersen M.L., Zanata S.M., Andreatini R., Tufik S., Vital M.A. Repeated intranigral MPTP administration: a new protocol of prolonged locomotor impairment mimicking Parkinson's disease. J Neurosci Methods 2008, 167:268-277.
40. Sabban E.L., Kvetnansky R. Stress-triggered activation of gene expression in catecholaminergic systems: dynamics of transcriptional events. Trends Neurosci 2001, 24:91-98.
41. Sancesario G., Giorgi M., D'Angelo V., Modica A., Martorana A., Morello M., Bengtson C.P., Bernardi G. Down-regulation of nitrergic transmission in the rat striatum after chronic nigrostriatal deafferentation. Eur J Neurosci 2004, 20:989-1000.
42. Selley M.L. Simvastatin prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced striatal dopamine depletion and protein tyrosine nitration in mice. Brain Res 2005, 1037:1-6.
43. Sharma S., Kumar K., Deshmukh R., Sharma P.L. Phosphodiesterases: regulators of cyclic nucleotide signals and novel molecular target for movement disorders. Eur J Pharmacol 2013, 714:486-497.
44. Shults C.W., Kimber T., Altar C.A. BDNF attenuates the effects of intrastriatal injection of 6-hydroxydopamine. NeuroReport 1995, 6:1109-1112.
45. Slivka A., Cohen G. Hydroxyl radical attack on dopamine. J Biol Chem 1985, 260:15466-15472.
46. Southwell A.L., Ko J., Patterson P.H. Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease. J Neurosci 2009, 29:13589-13602.
47. Sun M., Kong L., Wang X., Lu X.G., Gao Q., Geller A.I. Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson's disease. Brain Res 2005, 1052:119-129.
48. Thakur T., Sharma S., Kumar K., Deshmukh R., Sharma P.L. Neuroprotective role of PDE4 and PDE5 inhibitors in 3-nitropropionic acid induced behavioral and biochemical toxicities in rats. Eur J Pharmacol 2013, 714:515-521.
49. Tipton K.F., Singer T.P. Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds. J Neurochem 1993, 61:1191-1206.
50. Valikovics A. Investigation of the effect of vinpocetine on cerebral blood flow and cognitive functions. Ideggyogy Sz 2007, 60:301-310.
51. Vila M., Przedborski S. Targeting programmed cell death in neurodegenerative diseases. Nat Rev Neurosci 2003, 4:365-375.
52. Vila M., Ramonet D., Perier C. Mitochondrial alterations in Parkinson's disease: new clues. J Neurochem 2008, 107:317-328.
53. Wang A.L., Liou Y.M., Pawlak C.R., Ho Y.J. Involvement of NMDA receptors in both MPTP induced neuroinflammation and deficits in episodic-like memory in Wistar rats. Behav Brain Res 2010, 208:38-46.
54. Wang W.F., Wu S.L., Liou Y.M., Wang A.L., Pawlak C.R., Ho Y.J. MPTP lesion causes neuroinflammation and deficits in object recognition in Wistar rats. Behav Neurosci 2009, 123:1261-1270.
55. West A.R., Grace A.A. Striatal nitric oxide signaling regulates the neuronal activity of mid brain dopamine neurons in vivo. J Neurophysiol 2000, 83:1796-1808.
56. Wills E.D. Mechanism of lipid peroxide formation in animal. Biochem J 1996, 99:667-676.
57. Yan J., Xu Y., Zhu C., Zhang L., Wu A., Yang Y., Xiong Z., Deng C., Huang X.F., Yenari M.A., Yang Y.G., Ying W., Wang Q. Simvastatin prevents dopaminergic neurodegeneration in experimental parkinsonian models: the association with anti-inflammatory responses. PLoS One 2011, 6:e20945.
58. Yang L., Calingasan N.Y. Attenuation of MPTP neurotoxicity by rolipram, a specific inhibitor of phosphodiesterase IV. Exp Neurol 2008, 211:311-314.
59. Yokoyama H., Kuroiwa H., Yano R., Araki T. Targeting reactive oxygen species, reactive nitrogen species and inflammation in MPTP neurotoxicity and Parkinson's disease. Neurol Sci 2008, 29:293-301.
60. Zaitone S.A., Elmatty D.M.A., Elshazly S.M. Piracetam and vinpocetine ameliorate rotenone-induced Parkinsonism in rats. Indian J Pharmacol 2012, 44:774-779.
61. Zuccato C., Cattaneo E. Brain-derived neurotrophic factor in neurodegenerative diseases. Nat Rev Neurol 2009, 5:311-322.